Characterization of the antiviral effects of 2' carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus

Hepatology. 1994 Feb;19(2):398-411.

Abstract

This study was carried out to evaluate benefits and limitations of long-term therapy of hepatitis B virus infections with a nucleoside analog inhibitor of virus replication. The model we used was the domestic duck chronically infected with duck hepatitis B virus by in ovo infection. 2' Carbodeoxyguanosine was used as an inhibitor of viral DNA synthesis. In all animals examined there was a reduction in virus production during therapy. A dose of 2' carbodeoxyguanosine of 10 micrograms/kg every other day reduced the number of infected hepatocytes from greater than 95% to 25% to 50% in less than 3 mo, whereas a 10-fold higher dose produced a decline to less than 10%. Histological evaluation revealed mild to moderate liver injury in ducks receiving the higher dose of 2' carbodeoxyguanosine, suggesting that disappearance of infected hepatocytes may have been accelerated by a toxic effect of the drug. Drug treatment did not completely eliminate duck hepatitis B virus from any duck, and replication was restored in all hepatocytes within a few weeks to several months after antiviral therapy was terminated. Our results suggest that elimination of a chronic infection with a single inhibitor of replication may be difficult in a host that lacks an antiviral immune response capable of eliminating at least a portion of the infected hepatocytes and of ultimately producing antibodies capable of neutralizing residual virus.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Antiviral Agents / toxicity
  • Blotting, Southern
  • Cells, Cultured
  • Chronic Disease
  • DNA Replication / drug effects
  • DNA, Viral / biosynthesis
  • DNA, Viral / drug effects
  • Deoxyguanosine / analogs & derivatives*
  • Deoxyguanosine / pharmacology
  • Deoxyguanosine / therapeutic use
  • Deoxyguanosine / toxicity
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Ducks
  • Hepadnaviridae Infections / drug therapy*
  • Hepatitis B Virus, Duck / drug effects*
  • Hepatitis B Virus, Duck / genetics
  • Hepatitis B Virus, Duck / physiology
  • Liver / drug effects
  • Liver / microbiology
  • Liver / pathology
  • Viremia / drug therapy
  • Virus Replication / drug effects

Substances

  • Antiviral Agents
  • DNA, Viral
  • 2-amino-1,9-dihydro-9-(3-hydroxy-4-(hydroxymethyl)cyclopentyl)-6H-purine-6-one
  • Deoxyguanosine